| Literature DB >> 32793890 |
Esmé Waanders1,2,3, Zhaohui Gu1, Stephanie M Dobson4,5, Željko Antić2, Roland P Kuiper2, Charles G Mullighan6, Jeremy Chase Crawford7, Xiaotu Ma8, Michael N Edmonson8, Debbie Payne-Turner1, Maartje van de Vorst9, Marjolijn C J Jongmans2,3, Irina McGuire10, Xin Zhou8, Jian Wang8, Lei Shi11, Stanley Pounds11, Deqing Pei11, Cheng Cheng11, Guangchun Song1, Yiping Fan8, Ying Shao8, Michael Rusch8, Kelly McCastlain1, Jiangyan Yu2, Ruben van Boxtel2, Francis Blokzijl12,13, Ilaria Iacobucci1, Kathryn G Roberts1, Ji Wen1, Gang Wu8, Jing Ma1, John Easton8, Geoffrey Neale14, Scott R Olsen14, Kim E Nichols15, Ching-Hon Pui15, Jinghui Zhang8, William E Evans16, Mary V Relling16, Jun J Yang16, Paul G Thomas7, John E Dick4,5.
Abstract
Relapse of acute lymphoblastic leukemia (ALL) remains a leading cause of childhood death. Prior studies have shown clonal mutations at relapse often arise from relapse-fated subclones that exist at diagnosis. However, the genomic landscape, evolutionary trajectories and mutational mechanisms driving relapse are incompletely understood. In an analysis of 92 cases of relapsed childhood ALL, incorporating multimodal DNA and RNA sequencing, deep digital mutational tracking and xenografting to formally define clonal structure, we identify 50 significant targets of mutation with distinct patterns of mutational acquisition or enrichment. CREBBP, NOTCH1, and Ras signaling mutations rose from diagnosis subclones, whereas variants in NCOR2, USH2A and NT5C2 were exclusively observed at relapse. Evolutionary modeling and xenografting demonstrated that relapse-fated clones were minor (50%), major (27%) or multiclonal (18%) at diagnosis. Putative second leukemias, including those with lineage shift, were shown to most commonly represent relapse from an ancestral clone rather than a truly independent second primary leukemia. A subset of leukemias prone to repeated relapse exhibited hypermutation driven by at least three distinct mutational processes, resulting in heightened neoepitope burden and potential vulnerability to immunotherapy. Finally, relapse-driving sequence mutations were detected prior to relapse using deep digital PCR at levels comparable to orthogonal approaches to monitor levels of measurable residual disease. These results provide a genomic framework to anticipate and circumvent relapse by earlier detection and targeting of relapse-fated clones.Entities:
Keywords: acute lymphoblastic leukemia; clonal evolution; genomics; hypermutation; neoepitopes; relapse
Mesh:
Year: 2020 PMID: 32793890 PMCID: PMC7418874 DOI: 10.1158/0008-5472.BCD-19-0041
Source DB: PubMed Journal: Blood Cancer Discov ISSN: 2643-3230